Back to search results

A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

Abroad (travel likely)RecruitingPHASE2

Conditions

Minimal Change Disease (MCD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Contact: Study coordinator (Max Schuller, M.D. Ph.D.) · max.schuller@medunigraz.at · 004331638512170
    Contact: Study coordinator (Kathrin Eller, M.D. Ph.D.)

  • Department of Internal Medicine IV, Nephrology and Hypertension, Innsbruck, Austria

    Contact: Study coordinator (Andreas Kronbichler, M.D. Ph.D.) · andreas.kronbichler@i-med.ac.at · 004351250425855
    Contact: Study coordinator (Philipp Gauckler, M.D.) · philipp.gauckler@i-med.ac.at
    Contact: Principal Investigator (Andreas Kronbichler, M.D. Ph.D.)

  • 6. Medizinische Abteilung mit Nephrologie & Dialyse, Klinik Ottakring, Vienna, Austria

    Contact: Study coordinator (Sara Ksiazek, M.D.) · sara.ksiazek@hotmail.com · 00431491502610
    Contact: Study coordinator (Marcus Säemann, M.D.)

  • Laboratory of Immunology, Nice University Hospital (CHU de Nice), Côte d'Azur University, Nice, France

    Contact: Study coordinator (Barbara Seitz-Polski, M.D. Ph.D.) · seitz-polski.b@chu-nice.fr · 0033492037917
    Contact: Study coordinator (Celine Fernandez, M.D.) · fernandez.c3@chu-nice.fr

  • Hôpital Henri-Mondor, Paris, France

    Contact: Study coordinator (Vincent Audard, M.D.) · vincent.audard@aphp.fr · 0033149812457

  • III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Contact: Study coordinator (Elisabeth Meister, M.D.) · e.meister@uke.de · 004940741054167
    Contact: Study coordinator (Tobias Huber, M.D.)
View source on ClinicalTrials.gov(opens in a new tab)